Amorphism of compound A benzoate, preparation method thereof, and amorphism-containing medicinal composition

A technology of benzoate and benzoate chemistry, applied to the amorphous form of compound A benzoate and its preparation, and the field of pharmaceutical compositions containing the amorphous form, which can solve the problem of lack of hydrophobic transmembrane domains and other problems , to achieve the effect of being conducive to preparation and use, simple method and high stability

Active Publication Date: 2017-01-25
SHENZHEN SALUBRIS PHARMA CO LTD
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A soluble protein form of DPP-IV exists in serum that is structurally and functionally identical to the membrane-bound protein form but lacks the hydrophobic transmembrane domain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amorphism of compound A benzoate, preparation method thereof, and amorphism-containing medicinal composition
  • Amorphism of compound A benzoate, preparation method thereof, and amorphism-containing medicinal composition
  • Amorphism of compound A benzoate, preparation method thereof, and amorphism-containing medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] The preparation of embodiment 1 compound A

[0041] According to the methods of Examples 2 and 3 of WO2011079778 specification, compound A was prepared using the following technical synthesis route:

[0042] The obtained compound A, 1 H-NMR (400MHz, DMSO, ppm): δ7.96(m,1H),7.36(br,1H),7.29(d,1H),5.23(s,2H),3.15(m,3H),2.72( m,2H),2.23(s,3H),1.78(d,1H),1.64(d,1H),1.47(m,1H),1.12(m,1H).MS: m / z,343(100% ,M+1).

[0043]

[0044] Concrete preparation steps are as follows:

[0045] Step A. 1-Bromo-4-fluoro-2-(methylisothiocyanate)benzene (2)

[0046]To a solution of 1-bromo-2-(bromomethyl)-4-fluorobenzene (1,5.36 g, 20.0 mmol) in DMF (20 mL) was added sodium iodide (1.20 g, 8.00 mmol) and potassium thiocyanate (3.88g, 40.0mmol). The mixture was heated to 80° C. for 12 h under a nitrogen atmosphere, cooled to room temperature, 100 mL of water was added thereto, and extracted with ethyl acetate (50 mL×2), the combined organic layers were washed with saturated brine, a...

Embodiment 2

[0062] The preparation of embodiment 2 compound A benzoate

[0063] Prepare 95% ethanol solution: add 228mL ethanol to a 500mL beaker, add 12mL water, stir evenly, set aside.

[0064] Take 2.14g of benzoic acid, add 10mL of 95% ethanol at room temperature and stir to dissolve, and set aside; add 60g of compound A refined product and 120mL of 95% ethanol to a 500mL reaction bottle, stir, dissolve, filter, and wash with 18ml of 95% ethanol; The ethanol solution of benzoic acid was added dropwise at 15 °C. After the dropwise addition was completed, the mixture was washed with 95% ethanol and dried under reduced pressure to constant weight to obtain 42.4 g of compound A benzoate.

[0065] 1 HNMR (DMSO-d 6 ,400MHz,ppm)δ7.96-7.88(m,3H),7.45-7.26(m,5H),6.80(brs,3H),5.21(q,2H),3.41(d,1H),3.11-3.08( m,2H),2.91-2.79(m,2H),2.23(s,3H),1.95-1.91(m,1H),1.78-1.74(m,1H),1.57-1.42(m,2H).MS: m / z,341(100%,M-1),343(100%,M+1).

Embodiment 3

[0066] The amorphous preparation of embodiment 3 compound A benzoate

[0067] Put 5.0 g of compound A benzoate in 25 mL of dichloromethane solvent, stir to dissolve, and concentrate to dryness at 20°C to 30°C to obtain a bubble-like product, which is vacuum-dried at room temperature to prepare an amorphous form of compound A benzoate .

[0068] The amorphous X-ray diffraction pattern of gained compound A benzoate is as figure 1 As shown, the DSC spectrum is as image 3 As shown, the TG spectrum is as Figure 5 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of preparation of medicinal compositions, and particularly relates to an amorphism of compound A benzoate, a preparation method thereof and an amorphism-containing medicinal composition.

Description

technical field [0001] The invention belongs to the field of preparation of pharmaceutical compounds, in particular to an amorphous compound A benzoate, a preparation method thereof, and a pharmaceutical composition containing the amorphous. Background technique [0002] Dipeptidyl peptidase IV (Dipeptidyl peptidase IV, DPP-IV) is a serine protease that can specifically hydrolyze the Xaa-Pro or Xaa-Ala dipeptide at the N-terminal of a polypeptide or protein. DPP-IV is an atypical serine protease, and the Ser-Asp-His catalytic triad in the C-terminal region is different from typical serine proteases, and is arranged in reverse order. DPP-IV is a type II membrane integral protein, which is widely distributed in various tissues of mammals. DPP-IV is expressed on the surface of differentiated epithelial cells such as intestine, liver, renal proximal tubules, prostate, corpus luteum, and leukocyte subtypes such as lymphocytes and macrophages. A soluble protein form of DPP-IV ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/04A61K31/53A61P3/10
CPCC07D401/04
Inventor 谭颂德张昌中黄群辉邓运植建琼
Owner SHENZHEN SALUBRIS PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap